

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Thermo Fischer Scientific: Cardiac markers (2015)
	- Vifor International : Heart failure (2015)
	- Astra Zeneca : Platelet inhibition (2015)
	- Astra Zeneca : Antiplatelet treatment (2016)
Antunes Manuel J	Nothing to be declared (2015-2016)
Bucciarelli-Ducci Chiara	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Circle Cardiovascular Imaging, Inc : Imaging software (2015)
	- Circle Cardiovascular Imaging, Inc : Software for cardiac MRI imaging analysis (2016)
	D - Research funding (departmental or institutional) National Institute of Health Research (NIHR) - United Kingdom : Health research (2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer Healthcare : Aspirin (2015)
	- Sanofi Aventis : Clopidogrel (2015)
	- Daiichi Sankyo : Prasugrel (2015)
	- Eli Lilly : Prasugrel (2015)
	- Novartis : Serelaxin, LCZ696 (2015)
	- Pfizer : Apixaban (2015-2016)
	- Bristol Myers Squibb : Apixaban (2015-2016)
	- Servier : ivabradine (2015-2016)
	- Astra Zeneca : Ticagrelor (2015-2016)
	- Ferrer Internacional : Trinomia (polypill) (2015-2016)
	- Bayer : Aspirin, rivaroxaban (2016)
	- Abbott : BVS (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	- MEDSCAPE-the heart.og : Inespecific (2016)
	- Novartis : Serelaxin, ACZ885, AHF Academy (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Ticagrelor (2015-2016)
	E - Research funding (personal) Astra Zeneca : Ticagrelor (2015)
	- BMS : CV013-011 - STANDUP-AHF trial (2016)
	- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)
	- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016)
	- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
Caforio Alida L P	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Menarini : heart failure, speaker fees (2015-2016)
	- Genzyme : rare cardiac disease, Fabry disease, speaker fees (2015-2016)
	- Shire HGT : rare cardiac disease, Fabry disease, speaker fees, consultant fees (2015-2016)
Crea Filippo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Advisory Board (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boehringer-Ingelheim: Phd Research Founding (2016)
	- Biotronik : Phd Research Founding (2016)
	C - Receipt of royalties for intellectual property Edizioni Edra : Rugarli - Medicina Interna Sistematica (2015)
	- Springer : Coronary microvascular dysfunction (2015-2016)
	D - Research funding (departmental or institutional) Boehringer-Ingelheim : PHD Research funding (2015)
	- Biotronik : PHD Research funding (2015)
Goudevenos John A	Nothing to be declared (2015-2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bristol Myers Squibb : Antithrombotic treatment (2015-2016)
	- Astra Zeneca : Anti-thrombotic treatment (2015-2016)
	- Boehringer-Ingelheim : Anti-thrombotic treatment (2015-2016)
	- Pfizer : Anti-thrombotic treatment (2015-2016)
	- Bayer AS : Anti-thrombotic treatment (2015-2016)
	- Sanofi Aventis : Cholesterol lowering treatment (2015-2016)
	- Merck Sharp & Dohme : Cholesterol lowering treatment (2015-2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Merck Sharp & Dohme : Lipid-lowering treatment (2015)
	- Boehringer-Ingelheim : Anti-thrombotic treatment (2015-2016)
	- Sanofi Aventis : Lipid lowering treatment (2015-2016)
Hindricks Gerhard	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific : IC, CRT, Catheter Ablation (2015)
	- Biotronik : ICD CRT (2015)
	- St Jude Medical : ICD, CRT, Catheter Ablation (2015)
	- Boston Scientific : CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
	- Biotronik : CIEDs and interventional electrophysiology (2016)
	D - Research funding (departmental or institutional) Daiichi Sankyo : atrial fibrillation, anticoagulation (2015)
	- Boston Scientific : ICD, CRT, Catheter Ablation (2015)
	- St Jude Medical : ICD, CRT, Catheter Ablation (2015)
	- Biotronik : ICD, CRT, Catheter Ablation (2015)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Hindricks Gerhard	- Zoll Medical : wearable ICD (2015)
	- Boston Scientific : CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
Ibanez Borja	D - Research funding (departmental or institutional). - Astra Zeneca: I am Co-PI of a multicenter scientific grant for a study on behavioral change for primary prevention, NO drugs or products involved. (2015-2016)
James Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer : Anti coagulation (2016)
	- Boston Scientific : Stents (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer: anti coagulation (2015)
	- Astra Zeneca : platelet inhibition (2015)
	- Medicines Company : Anti thrombotics (2016)
	- Astra Zeneca : Antiplatelet (2016)
	- Abbott : Stents (2016)
	- Boston Scientific : stents (2016)
	D - Research funding (departmental or institutional) The Medicines Company : anti coagulation (2015)
	- Astra Zeneca : Anti platelet (2015)
	- Abbot Vascular : stents (2015)
	- Astra Zeneca : Anti thrombotics (2016)
Kastrati Adnan	Nothing to be declared (2015-2016)
Lenzen Mattie	Nothing to be declared (2015-2016)
Prescott Eva	Nothing to be declared (2015)

23/08/2017 4/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Prescott Eva	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astrazeneca : Microvascular disease (2016)
Roffi Marco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Johnson & Johnson : coronary catheters (2015-2016)
	- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)
	- Terumo Inc : coronary catheters (2016)
	D - Research funding (departmental or institutional) Biosensors : devices (2015)
	- Boston Scientific : devices (2015-2016)
	- Medtronic : devices (2015-2016)
	- Biotronik : devices (2015-2016)
	- Terumo Inc : devices (2015-2016)
	- Abbott Vascular : devices (2015-2016)
Valgimigli Marco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: Oral anticoagulation (2015)
	- Astra Zeneca : Antiplatelet agents (2016)
	- Terumo Inc : Coronary stent (2016)
	- Abbott Vascular : Coronary Stent (2016)
	- Sinomed : Coronary stent (2016)
	- Bayer : Oral anticoagulation (2016)
	- Correvio : Tirofiban (2016)
	D - Research funding (departmental or institutional) Astra Zeneca : Anti platelet agents (2016)
	- Medicure : Antiplatelet agents (2016)
	- Terumo Inc : Coronary stent (2016)

23/08/2017 5/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Valgimigli Marco	- The Medicines Company : parenteral anticoagulation (2016)
Varenhorst Christoph	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Pfizer : apixaban (2015)
	- Bristol Myers Squibb : apixaban (2015)
	- CSL Behring : bleeding disorder therapies (2015)
	- Boehringer-Ingelheim : dabigatran (2015)
	- Astra Zeneca : ticagrelor (2015)
	- Astra Zeneca : Acute Coronary Syndromes (2016)
	- Boehringer-Ingelheim : Antithrombotics (2016)
	- Pfizer : Antithrombotics (2016)
	- Bristol Myers Squibb : Antithrombotics (2016)
	- Bayer AG : Antithrombotics (2016)
	- CSL Behring : Haemostasis (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca: ticagrelor (2015)
	- Astra Zeneca : Acute Coronary Syndromes (2016)
	D - Research funding (departmental or institutional) Medicines Company: bivalirudin (2015)
	- Astra Zeneca : ticagrelor, antidiabetics (2015)
	- Medicines Company : Antithrombotics (2016)
	- Astra Zeneca : RWE research (2016)
Vranckx Pascal	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer Healthcare: coagulation (2015)
	- Astra Zeneca : P2Y12 inhibition (2015)

23/08/2017 6/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Vranckx Pascal	- Daiichi Sankyo : NOAC (2015-2016)
	- Bayer Healthcare : NOAC (2015-2016)
Widimsky Petr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo : Antithrombotic agents (2015)
	- Eli Lilly : Antithrombotic agents (2015)
	- Abbott : Stents (2015)
	- Servier : Antiischemic agents (2015-2016)
	- Astra Zeneca : Antithrombotic agents (2015-2016)
	- Bayer : Antithrombotic agents (2015-2016)
	- Boehringer-Ingelheim : Antithrombotic agents (2015-2016)
	- Medtronic : Stents (2015-2016)

23/08/2017 7/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Amgen: Hyperlipidemia (2016)
	- Novartis : Hypertension (2016)
	- Boehringer-Ingelheim : Oral anticoagulation (2016)
	- Bayer Healthcare : Oral anticoagulation (2016)
	- Pfizer/BMS alliance : Oral anticoagulation (2016)
Aladashvili Alexander	Nothing to be declared (2016)
Antoniades Loizos	Nothing to be declared (2016)
Bajraktari Gani	Nothing to be declared (2016)
Baumbach Andreas	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca: Drugs (2016) - Keystone Heart: EMbolic Protection (2016)
	- Abiomed : LV Assist (2016)
	- Abbott Vascular : Stents (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott Vascular: Stents (2016)
Beauloye Christophe	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Speaker Fees (2016)
	D - Research funding (departmental or institutional) Astra Zeneca : Research Grant (2016)
	- Bayer : Research Grant (2016)
	- Medtronic : Research Grant (2016)
	- Pfizer : Research Grant (2016)
Beishenkulov Medet	Nothing to be declared (2016)
Benlamin Hisham	Nothing to be declared (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Berkinbayev Salim	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Servier : Cardiology (2016)
Bertelli Luca	Nothing to be declared (2016)
Bolognese Leonardo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra: antiplatelet therapy, antianginal Rx, stents (2016)
	D - Research funding (departmental or institutional) Astra Zeneca : antiplatelet therapy (2016)
Bugiardini Raffaele	Nothing to be declared (2016)
Bunc Matjaz	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Edwards Lifesciences: TAVI, proctor (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Medtronic : TAVI, proctor (2016)
Chettibi Mohamed	Nothing to be declared (2016)
Collet Jean-Philippe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc BMS : apixaban (2016)
	- Sanofi Aventis : CLOPIDOGREL (2016)
	- Medtronic : corevalve (2016)
	- Eli Lilly : PRASUGREL (2016)
	- Astra-Zeneca : ticagrelor (2016)
	- MSD : VORAPAXAR (2016)
	- Bayer Healthcare : xarelto (2016)
	D - Research funding (departmental or institutional) Bristol Myers Squibb : APIXABAN (2016)
	- Medtronic : COREVALVE (2016)
	- Stago : LABORATORY TEST (2016)
	- Eli Lilly : PRASUGREL (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)
	- ICAN : THROMBOSIS (2016)
	- Astra Zeneca : TICAGRELOR (2016)
Coman Ioan Mircea	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: anticoagulants (2016)
	- Johnson & Johnson : antithrombotic (2016)
	- Bayer AG : antithrombotic (2016)
	- Sanofi Aventis : dyslipidemia (2016)
	- Fournier Laboratories : dyslipidemia (2016)
	- Amgen Inc : dyslipidemia , (2016)
	- Novartis : HF (2016)
	- Vifor International : iron deficiency (2016)
	- Actelion : PHT (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: anticoagulants (2016)
	- Johnson & Johnson : antithrombotic (2016)
	- Bayer AG : antithrombotic (2016)
	- Sanofi Aventis : dyslipidemia (2016)
	- Amgen Inc : dyslipidemia (2016)
	- Fournier Laboratories : dyslipidemia (2016)
	- Novartis : HF (2016)
	- Vifor International : iron deficiency (2016)
	- Actelion : PHT (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Delgado Victoria	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott Vascular : Mitraclip (2016)
	D - Research funding (departmental or institutional) Boston Scientific : Pacemaker-Heart failure (2016)
	- Medtronic : Pacemaker-Heart failure (2016)
	- Biotronik : Pacemaker-Heart Failure (2016)
	- Edwards Lifesciences : Valvular heart disease (2016)
Dizdarevic-Hudic Larisa	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Pfizer: Ertugliflozin (subinvestigator in study) (2016)
Elsaesser Albrecht	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : ACS (2016)
	- Edwards Lifesciences : Aortic Valve (2016)
	- Daiichi Sankyo : Complications PCI (2016)
	- Novartis : Heart failure (2016)
	- St Jude Medical : OCT, PCI (2016)
	- Abbott Vascular : Scaffold (2016)
	- Elixir : Scaffold (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : ACS (2016)
	- Edwards Lifesciences : Aortic Valve (2016)
	- Daiichi Sankyo : Complications PCI (2016)
	- Novartis : Heart failure (2016)
	- St Jude Medical : OCT, PCI (2016)
	- Abbott Vascular : Scaffold (2016)
	- Elixir : Scaffold (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Fitzsimons Donna	Nothing to be declared (2016)
Gaemperli Oliver	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc GE-Healthcare: Imaging (2016) - Amgen Inc: PCSK9 (2016)
	- Servier : Procorolan (2016)
Gale Christopher Peter	 A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astrazeneca : ACS, heart failure (2016) - Novartis : heart failure (2016)
Occidente Occidente Anna Maria	· · ·
Garcia de Castro Ana Maria	Nothing to be declared (2016)
Gershlick Tony	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott Vascular : BAS (2016)
	- Medicines Company : cangrelor/ bivalirudin (2016)
	- Medtronic : DES (2016)
	- Astra Zeneca : Ticagrelor (2016)
	D - Research funding (departmental or institutional) Abbott Vascular : BAS (2016)
Gielen Stephan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca: Lectures, Advisory Board (2016)
	- Elixir : travel support (2016)
	- Sanofi Aventis : travel support ESC Congress (2016)
	- Novartis: Travel support for the German Cardiac Society meeting 2016, honorarium for lectures (2016)
	- Amgen Inc : Travel support for the German Cardiac Society meeting 2017, honorarium for lectures/advisory board (2016)
	- Biosensors : Travel support German Cardiac Society meeting 2015 (2016)
	C - Receipt of royalties for intellectual property Oxford University Press : Editor, Preventive Cardiology Textbook (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Gilard Martine	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer Healthcare : medication (2016)
	- Medtronic : TAVI (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : medication (2016)
	- Terumo Inc : OCT/stent (2016)
	- Abbott Vascular : Stent (2016)
	- Edwards Lifesciences : TAVI (2016)
	- GE Healthcare : Technology (2016)
Gudnason Thorarinn	Nothing to be declared (2016)
Gustiene Olivija	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca: Antiplatelet, ticagrelor (2016)
	- Krka Pharma : Atorvastatin (2016)
	- Berlin Menarini : Hypertension, infarction, Zofenopril (2016)
	- Servier : Stable angina, ivabradin (2016)
	D - Research funding (departmental or institutional). - Amgen : Amgen, Principal Investigator, Start of End of Study Visit Period: 2-Sept-16, The EOS Visit period will complete on 11-Nov-16 (2016)
Harjola Veli-Pekka	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Roche Diagnostics: Cardiac markers (2016)
	- Novartis : Heart failure (2016)
	- Orion : Heart failure (2016)
	- Pfizer : Venous thromboembolism (2016)
	- Merck Sharp & Dohme : Venous thromboembolism (2016)
	- Bayer AG : Venous thromboembolism (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Hayrapetyan Hamlet	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Servier : Arterial Hypertension (2016)
lakobishvili Zaza	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boehringer-Ingelheim, Novartis: Dabigatran, Sacubitril/valsartan (2016)
Ibrahimov Firdovsi	Nothing to be declared (2016)
Jeger Raban	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc B.Braun : DCB (Sequent Please) (2016)
	- St Jude Medical : TAVI (Portico) (2016)
	D - Research funding (departmental or institutional) B.Braun : BASKET-SMALL 2 (2016)
Juliebo Vibeke	Nothing to be declared (2016)
Kanakakis Ioannis- Georgios	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : ANTIPLATELETS (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc GlaxoSmithKline: ACS, INFLAMMATION (2016)
Karamfiloff Kiril	Nothing to be declared (2016)
Katus Hugo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo : Lixiana_NOAK (2016)
	- Astra Zeneca : Ticagrelor (2016)
	- Bayer Vital : Xarelto-NOAK (2016)
	D - Research funding (departmental or institutional) St Jude Medical : Biobank (2016)
	- Philips : MRT (2016)
Kedev Sasko	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific : Speaker fees (2016)
	- Medtronic : Speaker fees (2016)
	- Terumo Inc : Speaker fees (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Kedev Sasko	- Meril : Speaker fees (2016)
Knuuti Juhani	D - Research funding (departmental or institutional) Orion : Brain diseases (2016)
	- AC Immune : Brain diseses (2016)
	- Antaros : Endocrinology (2016)
	- Boehringer-Ingelheim : Neurology (2016)
	- MSD : Neurology (2016)
	- GE Gealthcare : Neurology (2016)
Kolh Philippe H	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Antiplatelet agents (2016)
	- B.Braun : Surgical instruments (2016)
Kristensen Steen Dalby	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Aspen : anti-thrombotics fondaparinux (2016)
	- Bayer AG : anti-thrombotics rivaroxiban (2016)
	- Astra Zeneca : anti-thrombotics Ticagrelor (2016)
	D - Research funding (departmental or institutional) Astra Zeneca : ticagrelor (2016)
Leclercq Christophe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific : devices (2016)
	- Medtronic : devices (2016)
	- Sorin Group : devices (2016)
	- St Jude Medical : devices (2016)
	- Biotronik : devices (2016)
	- Bayer Healthcare : DOAC (2016)
Legutko Jacek	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bracco Pharmaceutical: Interventional cardiology (IVUS, FFR) (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Legutko Jacek	- Volcano : Interventional cardiology (IVUS, FFR) (2016)
	- Abbott : Interventional cardiology (stents, balloons, wires, MitraClip, etc.) (2016)
	- Balton : Interventional cardiology (stents, balloons, wires, valves etc.) (2016)
	- Terumo Inc : Interventional cardiology (stents, balloons, wires, valves, OFDI, etc.) (2016)
	- Medtronic : Interventional cardiology, electrotherapy (stents, balloons, wires, valves, peacemakers, etc.) (2016)
	- Merck Sharp & Dohme : Simvastatin, ezetimib, etc. (2016)
	- Astra Zeneca : Tikagrelor (2016)
Lip Gregory Y H	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Medtronic : AF screening (2016)
	- BMS/Pfizer : Anticoagulation (2016)
	- Boehringer Ingelheim : Anticoagulation (2016)
	- Bayer/Janssen : Anticoagulation (2016)
	- Daiichi-Sankyo : Daiichi-Sankyo (2016)
	D - Research funding (departmental or institutional) BMS/Pfizer : AF Registries [unrestricted educational grant] (2016)
	- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Marandi Toomas	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Antithrombotics (2016)
Merkely Bela	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Sanofi Aventis : ACS (2016)
	- Medtronic : CRT course (2016)
	- Abbott : CRT/ICD (2016)
	- Servier : Heart Failure (2016)
	- Biotronik : ICD/CRT (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Merkely Bela	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott : cardiac rhythm management (2016)
	- Medtronic : cardiac rhythm management (2016)
	- Boston Scientific : CRT (2016)
Metzler Bernhard	Nothing to be declared (2016)
Morais Joao	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: Anticoagulants (2016)
	- Bayer Healthcare : Anticoagulants (2016)
	- Bristol Myers Squibb : Anticoagulants (2016)
	- Boehringer Ingelheim : Anticoagulants (2016)
	- Astra Zeneca : Antiplatelets (2016)
	- Merck Sharp & Dohme : Antiplatelets, lipids (2016)
	- Boston Scientific : Left Atrial Apendage Closure (2016)
	- Amgem : Lipids (2016)
Mourali Mohamed Sami	Nothing to be declared (2016)
Nedeljkovic Milan	Nothing to be declared (2016)
Neskovic Aleksandar N	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Medtronic : advisory board fees (2016)
	- Bayer Healthcare : honoraria, consultancy (2016)
	- Servier : speaker fees (2016)
	- PharmaSwiss : speaker fees (2016)
	- Astra Zeneca : speaker fees, advisory board fees, consultancy (2016)
	E - Research funding (personal). - Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-2015 (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Neumann Franz Josef	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boehringer-Ingelheim: Anticoagulant Therapy (2016)
	- Daiichi Sankyo : Anticoagulant therapy (2016)
	- Pfizer : Anticoagulant therapy (2016)
	- Bayer Healthcare : Anticoagulant therapy (2016)
	- Bristol Myers Squibb : Anticoagulant therapy (2016)
	- Astra Zeneca : Antiplatelet therapy (2016)
	- Boston Scientific : Interventional cardiology (2016)
	- Edwards Lifesciences : Transcatheter valves (2016)
	- Medtronic : Transcatheter valves (2016)
	D - Research funding (departmental or institutional) Bayer Healthcare : Anticoagulant therapy (2016) - Novartis : Heart failure (2016)
	- Pfizer : Heart failure (2016)
	- GlaxoSmithKline : Heart failure (2016)
	- Biotronik : Interventional Cardiology (2016)
	- Abbott Vascular : MitraClip (2016)
	- Edwards Lifesciences : Transcatheter Valves (2016)
	- Medtronic : Transcatheter Valves (2016)
Niemela Matti	Nothing to be declared (2016)
Niessner Alexander	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer: anticoagulation (2016)
	- Daiichi Sankyo : anticoagulation (2016)
	- Pfizer : anticoagulation (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Niessner Alexander	- Bristol Myers Squibb : anticoagulation (2016)
	- Boehringer-Ingelheim : anticoagulation, antidiabetic therapy (2016)
	- Novo-Nordisk : antidiabetic therapy (2016)
	- Astra Zeneca : antitthrombotic therapy (2016)
	- St Jude Medical : interventional cardiology (2016)
	D - Research funding (departmental or institutional) Boehringer-Ingelheim : atrial fibrillation (2016)
Parkhomenko Alexander	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc BHFZ: corvitin (2016)
	- Sanofi Aventis : enoxaparin (2016)
	- Servier : preductal (2016)
	- Bayer Healthcare : rivaroxaban (2016)
	- Astra Zeneca : ticagrelor (2016)
	D - Research funding (departmental or institutional) European Research Foundation FP7 : European Research Foundation FP7 grant 2014-2017 (2016)
Pereira Bruno	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Speaker Fee (2016)
	- Menarini : Speaker Fees (2016)
	- Merck Sharp & Dohme : Speaker Fees (2016)
Petursson Petur	Nothing to be declared (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Servier : Committee member, Speaker fee (2016)
	- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)
	- Amgen : Metabolic, Lipid (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Novartis: Heart Failure Prevention Initiatives (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Richter Dimitrios	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Menarini : CAD- hypertension (2016)
	- Novartis : hypertension (2016)
	- Abbott : lipids (2016)
	- Amgen : lipids (2016)
	- Sanofi Aventis : Lipids (2016)
	- Lilly : Lipids (2016)
	- Unilever : lipids (2016)
	- Merck Sharp & Dohme : lipids (2016)
	- Angelini : Lipids (2016)
	- Vianex : lipids (2016)
	- Galenica : Lipids (2016)
	- Teva Pharmaceutical Industries : lipids, hypertension (2016)
	- Swisspharma : lipids-hypertension (2016)
	- Astra Zeneca : lipids-thrombosis (2016)
	- Pfizer : lipids-thrombosis (2016)
	- Winmedica : lipids-thrombosis (2016)
	- Boehringer-Ingelheim : thrombosis (2016)
	- Bayer Healthcare : Thrombosis (2016)
Shaheen Sameh Moham	mad A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Novartis: Antihypertensives (2016)
	- Astra Zeneca : Antiplatelets (2016)
	- Pfizer : NOACS (2016)

23/08/2017 20/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Krka Pharma : Arterial Hypertension (2016)
	- Novartis : Arterial Hypertension, Heart Failure (2016)
	- Merck Sharp & Dohme : Atherosclerosis (2016)
	- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016)
	- Pfizer : General Cardiology (2016)
Simpson lain A	Nothing to be declared (2016)
Skoric Bosko	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Teva Pharmaceutical Industries Pliva : Diuron (2016)
	- Mylan : Dualtis (2016)
	- Novartis : Exforge HCT (2016)
	- Boehringer-Ingelheim : Jardiance (2016)
	- Berlin Chemie AG : Zofecard (2016)
Steg Philippe Gabriel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Servier : antianginal agents (2016)
	- Bayer : anticoagulants (2016)
	- Astra Zeneca : antiplatelet agents (2016)
	- Daiichi Sankyo : antiplatelet agents (2016)
	- Boehringer-Ingelheim : antithrombotics (2016)
	- Janssen-Cilag : antithrombotics (2016)
	- Sanofi Aventis : antithrombotics (2016)
	- GlaxoSmithKline : antithrombotics (2016)
	- Medicines Company : antithrombotics (2016)
	- Bristol Myers Squibb : antithrombotics (2016)

23/08/2017 21/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Steg Philippe Gabriel	- Lilly : antithrombotics and lipid lowering drugs (2016)
	- Novartis : consulting (2016)
	- Pfizer : Events adjudication committee (2016)
	- Amarin : Lipid compounds (2016)
	- CSL Behring : lipid lowering drugs (2016)
	D - Research funding (departmental or institutional) Sanofi Aventis : Clinical trial on lipids (2016)
	- Servier : Registry on coronary artery disease (2016)
Studencan Martin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Brilique (2016)
	- MSD : Esetimibe, Inegy (2016)
	- Medtronic : stents (2016)
Sujayeva Volha	Nothing to be declared (2016)
Tatu-Chitoiu Gabriel Petrisor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boehringer Ingelheim: Cardiology (2016)
Terkelsen Christian Juhl	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Medicine (2016)
	D - Research funding (departmental or institutional) Terumo Inc : Coronary angiography equipment (2016)
Thygesen Kristian	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott Laboratories: Diagnostics (2016)
Timoteo Ana Teresa	Nothing to be declared (2016)
Tousek Petr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Antiplatelet treatment (2016)
Windecker Stephan	D - Research funding (departmental or institutional) Boston Scientific : General Cardiology (2016)
	- St Jude Medical : General Cardiology (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Windecker Stephan	- Terumo Inc : General Cardiology (2016)
	- Bracco Pharmaceutical : General Cardiology (2016)
Xuereb Robert G	Nothing to be declared (2016)
Yakovlev Alexey	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Acute coronary syndrome (2016)
	- Boehringer-Ingelheim : Acute coronary syndrome (2016)
	- Sanofi Aventis : Acute coronary syndrome (2016)
Yildirir Aylin	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Novartis: Consultant (2016)
Zakke Ilja	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc BGP Products: Cardiology (2016)
Zamorano Gomez Jose Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Philips : 3D Echocardiography. (2016)
	- Servier : Clinical case presentation during ESC Cong 2016 (2016)
	- Pfizer : speaker CV risk factors. (2016)
	- MSD : speaker. CV risk factors (2016)
	D - Research funding (departmental or institutional) Edwards Lifesciences: Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)
	- Abbott : Epidemiology study of Mitral regurgitation (2016)
Zeymer Uwe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca: Antithrombotic therapy (2016)
	- Boehringer-Ingelheim : Antithrombotic therapy (2016)
	- Daiichi Sankyo : Antithrombotic therapy (2016)
	- Eli Lilly : Antithrombotic therapy (2016)
	- Sanofi Aventis : Antithrombotic therapy (2016)
	- Medicines Company : Antithrombotic therapy (2016)

23/08/2017 23/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Zeymer Uwe	- Bayer AG : Antithrombotic therapy (2016)
	- Pfizer : Antithrombotic therapyy (2016)
	- Bristol Myers Squibb : Antithtombotic therapy (2016)
	- Institut für Herzinfarktforschung Ludwigshafen, Germany : CRO (2016)
	- Medtronic : Devices (2016)
	- Zoll Medical : Devices (2016)
	- Novartis : Heart Failure (2016)
	- Amgen : Lipid lowering therapy (2016)
	- Merck Sharp & Dohme : Lipid lowering therapy, antithrombotic therapy (2016)
	D - Research funding (departmental or institutional) Novartis : Antihypertensive therapy (2016)
	- Daiichi Sankyo : antithrombotic therapy (2016)
	- Bristol Myers Squibb : Antithrombotic therapy (2016)
Ztot Samir	Nothing to be declared (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Aboyans Victor	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Amgen: Hyperlipidemia (2016)
	- Novartis : Hypertension (2016)
	- Boehringer-Ingelheim : Oral anticoagulation (2016)
	- Bayer Healthcare : Oral anticoagulation (2016)
	- Pfizer/BMS alliance : Oral anticoagulation (2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Antiplatelet treatment (2016)
Barbato Emanuele	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific: Education courses on rotational atherectomy (2016)
	- St Jude Medical : Educational courses on FFR (2016)
	D - Research funding (departmental or institutional) St Jude Medical: Unrestricted grant for an investigator-driven study (2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Pfizer : Apixaban (2016)
	- Bristol Myers Squibb : Apixaban (2016)
	- Bayer : Aspirin, rivaroxaban (2016)
	- Abbott : BVS (2016)
	- MEDSCAPE-the heart.og : Inespecific (2016)
	- Servier : ivabradine (2016)
	- Novartis : Serelaxin, ACZ885, AHF Academy (2016)
	- Astra Zeneca : Ticagrelor (2016)
	- Ferrer Internacional : Trinomia (polypill) (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Astra Zeneca : Ticagrelor (2016)

21/08/2017 25/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal) BMS: CV013-011 - STANDUP-AHF trial (2016) - Novartis: LCZ696 - PROMISE / PERSPECTIVE (2016)
	- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016)
	- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016)
Coca Antonio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Merck Serono: Bisoprolol-Amlodipine (2016)
	- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016)
	- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)
	- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016)
Collet Jean-Philippe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016)
	- Medtronic : corevalve (2016)
	- Eli Lilly : PRASUGREL (2016)
	- Astra-Zeneca : ticagrelor (2016)
	- MSD : VORAPAXAR (2016)
	- Bayer Healthcare : xarelto (2016)
	D - Research funding (departmental or institutional) Bristol Myers Squibb : APIXABAN (2016)
	- Medtronic : COREVALVE (2016)
	- Stago : LABORATORY TEST (2016)
	- Eli Lilly : PRASUGREL (2016)
	- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

21/08/2017 26/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	- ICAN : THROMBOSIS (2016)
	- Astra Zeneca : TICAGRELOR (2016)
Coman Ioan Mircea	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: anticoagulants (2016)
	- Johnson & Johnson : antithrombotic (2016)
	- Bayer AG : antithrombotic (2016)
	- Sanofi Aventis : dyslipidemia (2016)
	- Fournier Laboratories : dyslipidemia (2016)
	- Amgen Inc : dyslipidemia , (2016)
	- Novartis : HF (2016)
	- Vifor International : iron deficiency (2016)
	- Actelion : PHT (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: anticoagulants (2016)
	- Johnson & Johnson : antithrombotic (2016)
	- Bayer AG : antithrombotic (2016)
	- Sanofi Aventis : dyslipidemia (2016)
	- Amgen Inc : dyslipidemia (2016)
	- Fournier Laboratories : dyslipidemia (2016)
	- Novartis : HF (2016)
	- Vifor International : iron deficiency (2016)
	- Actelion : PHT (2016)
Delgado Victoria	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Abbott Vascular: Mitraclip (2016)

21/08/2017 27/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Delgado Victoria	D - Research funding (departmental or institutional) Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016)
	- Biotronik : Pacemaker-Heart Failure (2016)
	- Edwards Lifesciences : Valvular heart disease (2016)
Fitzsimons Donna	Nothing to be declared (2016)
Gaemperli Oliver	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc GE-Healthcare: Imaging (2016)
	- Amgen Inc : PCSK9 (2016)
	- Servier : Procorolan (2016)
Hindricks Gerhard	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific: CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
	- Biotronik : CIEDs and interventional electrophysiology (2016)
	D - Research funding (departmental or institutional) Boston Scientific : CIEDs and interventional electrophysiology (2016)
	- St Jude Medical : CIEDs and interventional electrophysiology (2016)
lung Bernard	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Edwards Lifesciences: Heart Valve Prostheses (2016)
Juni Peter	Nothing to be declared (2016)
Katus Hugo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Daiichi Sankyo: Lixiana_NOAK (2016)
	- Astra Zeneca : Ticagrelor (2016)
	- Bayer Vital : Xarelto-NOAK (2016)
	D - Research funding (departmental or institutional) St Jude Medical : Biobank (2016)

21/08/2017 28/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Katus Hugo	- Philips : MRT (2016)
Knuuti Juhani	D - Research funding (departmental or institutional) Orion : Brain diseases (2016)
	- AC Immune : Brain diseses (2016)
	- Antaros : Endocrinology (2016)
	- Boehringer-Ingelheim : Neurology (2016)
	- MSD : Neurology (2016)
	- GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc St Jude Medical : Echo course (2016)
	- Servier : Ischemic Heart Disease (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Bayer: NOAC (2016)
	- Medtronic : Structural disease (2016)
Leclercq Christophe	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boston Scientific: devices (2016)
	- Medtronic : devices (2016)
	- Sorin Group : devices (2016)
	- St Jude Medical : devices (2016)
	- Biotronik : devices (2016)
	- Bayer Healthcare : DOAC (2016)
McDonagh Theresa	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Vifor International : Ferrinject (2016)
	- Novartis : Honoraria (2016)
Piepoli Massimo Francesco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Servier : Committee member, Speaker fee (2016)

21/08/2017 29/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)
	- Amgen : Metabolic, Lipid (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Novartis: Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Boehringer-Ingelheim: anticoagulant, diabetes (2016)
	- Abbott Vascular : devices (2016)
	- Respicardia : devices (2016)
	- BioControl : devices (2016)
	- Novartis : heart failure (2016)
	- Cardiorentis : heart failure (2016)
	- Berlin Chemie AG : heart failure (2016)
	- Bayer Healthcare : heart failure (2016)
	- Vifor Pharma ltd : heart failure (2016)
	- CIBIEM : heart failure (2016)
	- Servier : heart failure, coronary artery disease (2016)
	- Amgen : heart failure, lipids (2016)
	- Pfizer : lipids (2016)
	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Respicardia: anticoagulant (2016)
	- BioControl : devices (2016)
	- DC Device : devices (2016)
	- Novartis : heart failure (2016)
	- Cardiorentis : heart failure (2016)

21/08/2017 30/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Ponikowski Piotr	- Bayer Healthcare : heart failure (2016)
	- CIBIEM : heart failure (2016)
	- Servier : heart failure, coronary artery disease (2016)
	- Amgen : heart failure, lipids (2016)
Richter Dimitrios	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Menarini : CAD- hypertension (2016)
	- Novartis : hypertension (2016)
	- Abbott : lipids (2016)
	- Amgen : lipids (2016)
	- Sanofi Aventis : Lipids (2016)
	- Lilly : Lipids (2016)
	- Unilever : lipids (2016)
	- Merck Sharp & Dohme : lipids (2016)
	- Angelini : Lipids (2016)
	- Vianex : lipids (2016)
	- Galenica : Lipids (2016)
	- Teva Pharmaceutical Industries : lipids, hypertension (2016)
	- Swisspharma : lipids-hypertension (2016)
	- Astra Zeneca : lipids-thrombosis (2016)
	- Pfizer : lipids-thrombosis (2016)
	- Winmedica : lipids-thrombosis (2016)
	- Boehringer-Ingelheim : thrombosis (2016)
	- Bayer Healthcare : Thrombosis (2016)



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Roffi Marco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Terumo Inc : coronary catheters (2016)
	- Johnson & Johnson : coronary catheters (2016)
	- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)
	D - Research funding (departmental or institutional) Boston Scientific : devices (2016)
	- Medtronic : devices (2016)
	- Biotronik : devices (2016)
	- Terumo Inc : devices (2016)
	- Abbott Vascular : devices (2016)
Shlyakhto Evgeny	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Krka Pharma : Arterial Hypertension (2016)
	- Novartis : Arterial Hypertension, Heart Failure (2016)
	- Merck Sharp & Dohme : Atherosclerosis (2016)
	- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016)
	- Pfizer : General Cardiology (2016)
Simpson lain A	Nothing to be declared (2016)
Windecker Stephan	D - Research funding (departmental or institutional) Boston Scientific : General Cardiology (2016)
	- St Jude Medical : General Cardiology (2016)
	- Terumo Inc : General Cardiology (2016)
	- Bracco Pharmaceutical : General Cardiology (2016)
Zamorano Gomez Jose Luis	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc Philips : 3D Echocardiography. (2016)
	- Servier : Clinical case presentation during ESC Cong 2016 (2016)

21/08/2017 32/33



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2016.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	- Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) D - Research funding (departmental or institutional).
	- Edwards Lifesciences: Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott: Epidemiology study of Mitral regurgitation (2016)

21/08/2017 33/33